Jyong Biotech Ltd.’s Lock-Up Period To Expire on December 15th (NASDAQ:MENS)

Jyong Biotech’s (NASDAQ:MENS) lock-up period will end on Monday, December 15th. Jyong Biotech had issued 2,666,667 shares in its initial public offering on June 17th. The total size of the offering was $20,000,003 based on an initial share price of $7.50. After the expiration of the company’s lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jyong Biotech in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Jyong Biotech Stock Down 1.8%

NASDAQ:MENS opened at $28.50 on Wednesday. The company has a fifty day moving average of $42.77. Jyong Biotech has a 12-month low of $6.01 and a 12-month high of $67.00.

Institutional Trading of Jyong Biotech

A hedge fund recently bought a new stake in Jyong Biotech stock. Millennium Management LLC purchased a new position in shares of Jyong Biotech Ltd. (NASDAQ:MENS) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 13,013 shares of the company’s stock, valued at approximately $512,000.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.